This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

27 candidates mapped to SDH-deficient disease pathways

All (27)established (4)clinical trial (4)preclinical (13)theoretical (6)
Belzutifan

Welireg

established

HIF-2α inhibitor

Hif Pseudohypoxia
Evidence Score
82
FDA Approved
Rogaratinib
clinical trial

Pan-FGFR inhibitor (FGFR1/2/3/4)

Fgfr SignalingEpigenetic Dysregulation
Evidence Score
76
Sunitinib

Sutent

established

Multi-kinase inhibitor (VEGFR/PDGFR/KIT)

Vegf SignalingMtor Pi3k Akt
Evidence Score
75
FDA Approved
Temozolomide

Temodar, Temodal

clinical trial

Alkylating agent

Epigenetic Dysregulation
Evidence Score
68
FDA Approved
Bevacizumab

Avastin

established

Anti-VEGF monoclonal antibody

Vegf Signaling
Evidence Score
65
FDA Approved
Tazemetostat

Tazverik

clinical trial

EZH2 inhibitor (PRC2 inhibitor)

Epigenetic Dysregulation
Evidence Score
65
FDA Approved
Telaglenastat

CB-839

clinical trial

Glutaminase inhibitor

Glutamine Dependency
Evidence Score
60
Olaparib

Lynparza

preclinical

PARP inhibitor (PARP1/2)

Sdh Driven HrdOxidative Stress Ros
Evidence Score
58
FDA Approved
Regorafenib

Stivarga

established

Multi-kinase inhibitor (VEGFR/KIT/PDGFR/FGFR/RAF)

Vegf SignalingMtor Pi3k Akt
Evidence Score
58
FDA Approved
Everolimus

Afinitor

preclinical

mTOR inhibitor (rapalog)

Mtor Pi3k Akt
Evidence Score
55
FDA Approved
Azacitidine

Vidaza

preclinical

DNA methyltransferase inhibitor (hypomethylating agent)

Epigenetic Dysregulation
Evidence Score
52
FDA Approved
Decitabine

Dacogen

preclinical

DNA methyltransferase inhibitor (hypomethylating agent)

Epigenetic Dysregulation
Evidence Score
50
FDA Approved
Daporinad (FK866)

APO866

preclinical

NAMPT inhibitor (NAD⁺ biosynthesis inhibitor)

Nad MetabolismOxidative Stress Ros
Evidence Score
48
Niraparib

Zejula

theoretical

PARP inhibitor (PARP1/2)

Sdh Driven Hrd
Evidence Score
45
FDA Approved
Hydroxychloroquine

Plaquenil

preclinical

Autophagy inhibitor (lysosomal alkalinizer)

Autophagy Survival
Evidence Score
42
FDA Approved
Erdafitinib

Balversa

theoretical

Pan-FGFR inhibitor (FGFR1/2/3/4), FDA-approved

Fgfr Signaling
Evidence Score
42
FDA Approved
Metformin

Glucophage

preclinical

Biguanide / Complex I inhibitor / AMPK activator

Mtor Pi3k AktOxidative Stress Ros
Evidence Score
40
FDA Approved
Ascorbic Acid (High-dose IV)
preclinical

TET enzyme cofactor / α-KG-dependent dioxygenase activator

Epigenetic DysregulationOxidative Stress Ros
Evidence Score
38
DENSPM (N1,N11-Diethylnorspermine)
preclinical

Polyamine analogue / SSAT inducer

Polyamine MetabolismOxidative Stress Ros
Evidence Score
38
Dichloroacetate (DCA)
preclinical

Pyruvate dehydrogenase kinase inhibitor

Hif PseudohypoxiaOxidative Stress Ros
Evidence Score
35
Birabresib

OTX015, MK-8628

theoretical

BET bromodomain inhibitor (pan-BRD2/3/4)

Epigenetic Dysregulation
Evidence Score
33
Ceralasertib

AZD6738

preclinical

ATR kinase inhibitor

Atrx Alt Replication Stress
Evidence Score
33
Panobinostat

Farydak

theoretical

Pan-HDAC inhibitor

Epigenetic Dysregulation
Evidence Score
30
FDA Approved
AZD3965
preclinical

MCT1 inhibitor (monocarboxylate transporter 1 inhibitor, SLC16A1)

Succinate Immune Evasion
Evidence Score
30
Pevonedistat

TAK-924

preclinical

NAE inhibitor (neddylation inhibitor, NEDD8-activating enzyme inhibitor)

Neddylation
Evidence Score
30
Enasidenib

Idhifa

theoretical

IDH2 inhibitor

Epigenetic Dysregulation
Evidence Score
28
FDA Approved
Epacadostat

INCB024360

theoretical

IDO1 inhibitor (indoleamine 2,3-dioxygenase 1 inhibitor)

Succinate Immune Evasion
Evidence Score
22